Sotera Health Company Q3 Earnings Lag Estimates

CODX Stock  USD 1.01  0.05  4.72%   
Slightly above 61% of Co Diagnostics' investor base is looking to short. The analysis of overall sentiment of trading Co Diagnostics stock suggests that many investors are alarmed at this time. Co Diagnostics' investing sentiment can be driven by a variety of factors including economic data, Co Diagnostics' earnings reports, geopolitical events, and overall market trends.
  
Sotera Health delivered earnings and revenue surprises of -10.53 percent and 2.05, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock

Read at zacks.com
zacks News
  

Co Diagnostics Fundamental Analysis

We analyze Co Diagnostics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Co Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Co Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Ratio

Current Ratio Comparative Analysis

Co Diagnostics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Co Diagnostics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Co Diagnostics stock to make a market-neutral strategy. Peer analysis of Co Diagnostics could also be used in its relative valuation, which is a method of valuing Co Diagnostics by comparing valuation metrics with similar companies.

Peers

Co Diagnostics Related Equities

NAOVNanoVibronix   9.23   
0%
100.0%
VVOSVivos Therapeutics   8.47   
0%
91.0%
MOVEMovano   8.18   
0%
88.0%
NPCENeuropace   7.78   
0%
84.0%
CLPTClearpoint Neuro   6.76   
0%
73.0%
SENSSenseonics Holdings   6.67   
0%
72.0%
TIVCTivic Health   4.17   
0%
45.0%
RPIDRapid Micro   3.60   
0%
39.0%
NVNOEnVVeno Medical   3.33   
0%
36.0%
NURONeuroMetrix   2.41   
0%
26.0%
HSCSHeart Test   1.91   
0%
20.0%
INGNInogen   1.85   
0%
20.0%
BBLGBone Biologics   1.63   
0%
17.0%
IINNInspira Technologies   0.74   
0%
8.0%
BJDXBluejay Diagnostics   0.57   
0%
6.0%
CVRXCVRx   0.54   
0%
5.0%
SRDXSurModics   0.36   
0%
3.0%
RSLSReShape Lifesciences   0.54   
5.0%
0%
BMRABiomerica   3.13   
33.0%
0%

Additional Tools for CODX Stock Analysis

When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.